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The aim of the present study was to explore the hedonic eﬀects of D2 receptor agonist, quinpirole and D2 receptor antagonist, and
sulpiride alone or in combination with a low dose of 17β-E2-estradiol (17β-E2) in the adult ovariectomized female rats (OVX).
OVX rats of Wistar strain were used in all experiments. Two weeks after surgery rats were chronically treated with vehicle, a low
dose of 17β-E2 (5.0μg/rat), quinpirole (0.1mg/kg), sulpiride (10.0mg/kg), quinpirole plus 17β-E2, or sulpiride plus 17β-E2 for
14 days before the forced swimming test. We found that sulpiride signiﬁcantly decreased immobility time in the OVX females. A
combinationofsulpiridewithalowdoseof17β-E2 inducedmoreprofounddecreaseofimmobilitytimeintheOVXratscompared
to the rats treated with sulpiride alone. On the contrary, quinpirole failed to modify depression-like behavior in the OVX rats. In
addition, quinpirole signiﬁcantly blocked the antidepressant-like eﬀect of 17β-E2 in OVX rats. Thus, the D2 receptor antagonist
sulpiride alone or in combination with a low dose of 17β-E2 exerted antidepressant-like eﬀect in OVX female rats, while the D2
receptor agonist quinpirole produced depressant-like proﬁle on OVX rats.
1.Introduction
Depressive disorders belong to the most frequent diseases
worldwide showing a lifetime prevalence of up to 20% [1, 2].
The traditional focus on a prominent participation of the
central serotonergic and noradrenergic systems in the mech-
anisms of depression is generally accepted [3, 4]. However,
recent evidences suggest that the dysfunction of the central
dopaminergic pathways may be a critical component of
the neurobiological basis of depression [5–8]. The mainfold
eﬀects of dopamine (DA) are mediated by two structurally
and functionally diﬀerent classes of G protein-coupled
receptors, termed D1 and D2, originally distinguished by
their ability to activate (D1 class) or inhibit (D2 class)
adenylate cyclase [9]. The D2 receptors play important role
in regulating DA transmission [9]. Together, D2 receptors
and the DA transporter (DAT) proteins provide control over
synaptic DA signaling, as evidenced by behavioral abnormal-
ities that accompany D2 receptors and DAT gene ablation
[10,11].Theseﬁndingsunderscorethecoordinatednatureof
DA homeostasis that, once perturbed, may lead to multiple
neuropsychiatric disorders. Behavioral and biochemical data
indicate involvement of a dopaminergic neurotransmitter
system in the pathophysiology of depression, as well as in the
mechanism of action of antidepressant drugs [12–16]. It has
been shown that mesolimbic dopamine pathways are impor-
tant to goal-directed behaviors, and that the hypofunction
of this system may mediate anhedonia and a motivational
apathy [17], that is, behaviors which are the key features of
depression. Because at least some of the D2-receptor ligands
investigated have selectivity for dopamine autoreceptors, it is
speculated that the dopamine autoreceptor may be a target
for the action of psychotropic drugs [18].
A number of clinical studies have shown a therapeutic
eﬃcacy of D2 antagonists (sulpiride and raclopride) in
diﬀerent types of depression. In fact, various studies suggest
that sulpiride given in low doses (100–300mg/day) may
be an appropriate treatment of slightly depressed patients,
including those suﬀering from endogenous depression [19,
20]. Therapeutic eﬀect of sulpiride was also evaluated
in patients with major depression [21]. Furthermore, the
D2 receptors have been implicated in major depression2 ISRN Pharmacology
by clinical evidence from neuroimaging and postmortem
and studies [4, 22, 23]. Also, low-dose atypical antipsy-
chotics (which increase extracellular levels of dopamine
and norepinephrine, but not serotonin, in the prefrontal
cortex) appear eﬀectiveinthepharmacotherapyoftreatment
resistant depression [24, 25]. Although eﬀective antide-
pressants tend to be useful across the range of depressive
symptoms, there is some evidence that dopaminergic agents
are particularly useful for reduced positive aﬀect and for
psychomotor symptoms [12, 17]. Nevertheless, there are
many controversies about the exact role of DA in depression
[6, 7].
On the other hand, estrogens have powerful eﬀects
beyond their role in reproduction. Estrogens have been sug-
gested to aﬀect several psychiatric and neurodegenerative
diseases including anxiety, depression, schizophrenia, and
Alzheimer’s disease [26, 27]. In female rodents, naturally
occurring changes in experimental depression-like behavior
have been observed [28–30]. In our recent studies we
reported that depression-like behavior increases during the
proestrous and estrous [31]. In addition to the physiological
actions of endogenous steroid secretions on the female
depression state, our experiments have also demonstrated
thattheantidepressanteﬀectofclomipraminevariesthrough
the estrous cycle [31, 32]. Furthermore, experimental evi-
dences have shown that estradiol exerts antidepressant-like
eﬀect in paradigms used to assess the antidepressant potency
of drugs [29, 30, 33] .H u m a ns t u d i e sh a v ed e m o n s t r a t e d
that the lifetime prevalence rate of mood disorders is
approximately two times more frequent in women than in
men [28, 34]. The increased prevalence of mood disruptions
during the reproductive years and the potential for mood
disorders to occur at times when estrogen levels are changing
[35]. Indeed, increased risk of aﬀective disorders in women
is related to hormonal changes who are premenstrual, post-
partum, and hypoestrogenic due to the medical surgery or
menopause [36, 37]. In spite of this, preclinical data exam-
ining the eﬀects of antidepressants on either behavioral,
physiological, or neurochemical parameters, have mainly
used males subjects until recently.
Moreover, it is well established that estrogens may
also modulate the central DA functions. Prolonged estro-
gen administration induces downregulation of presynap-
tic dopamine activity and produces a dopamine receptor
supersensitivity that results in a release from the inhibitory
action of these receptors and enhancement of stimulated
dopamine release [38]. On the other hand, DA also can
inﬂuence ovary hormonal system. So, estrogen receptors
(ERs) can be activated (in the absence of cognate ligand) by
the neurotransmitter DA [39] and by dopaminergic ligands
[40, 41]. This implies that ligand-independent activation
of ERs by DA might organize a unique set of behavior
in contrast to the ligand-dependent activation of ERs
by estrogen. Thus, such close interactions between ovary
hormonal and dopaminergic neurotransmitter systems then
itisofinteresttoelucidatetheinvolvementofD2 receptors in
depression-like state under conditions of estrogen deﬁciency,
that is, under such critical conditions that are contributed to
produce the profound mood impairments in females.
In our preliminary experiments, we were not able to
ﬁnd any eﬀects for D2-receptor agonist quinpirole and
D2-receptor antagonist sulpiride after acute administration
alone or in combination with 17β-estradiol (17β-E2)o n
depression-like behavior in adult ovariectomized (OVX) rats
(data are not shown). However, we assumed that eﬀects
of DA drugs can be diﬀerent after acute and chronic
administration in OVX rats. In order to study the behavioral
eﬀectsofDAdrugsaloneorincombinationwith17β-E2 after
repeated treatment, the present study was created.
The aim of this work was to study the eﬀects of
administration of D2 receptor agonist quinpirole and D2
receptor antagonist sulpiride injected chronically for 14 days
alone or in combination with 17β-E2 on depression-like
behavior in adult OVX rats. The forced swimming test used
in the present study has been behaviorally, physiologically,
and pharmacologically validated as an animal test model of
depression in rodents [42]. In the experiment OVX rats and
OVX rats with administration of 17β-E2 were used.
2. Methods
2.1. Subjects. A total number of 60 adult female rats of
Wistar strain (purchased from Rappolovo, Russia) weighing
180–200g were used. For at least a week prior to the
experiments, the rats were housed six to a cage under
standard environmental conditions: constant temperature
of 23 ± 1◦C, 60% humidity, 12h light/dark cycle (light on
8:00 a.m.), food and water ad libitum. All experiments were
carried out in accordance with the guide for care and use
of Laboratory Animals published by the national Institute
of Health (National Research council, publication no. 85-
23, revised in 1996), and the Animal Welfare Assurance
Renewal for Pavlov Institute of Physiology. The rationale,
design, and methods of this study have been approved by
the Ethical Committee for Animal Research, Institute of
Experimental Medicine. All animals were gently handled
by experienced keepers from the facility each day for a
week prior to experimental procedures. Any environmental
or physical stress was avoided in order to habituate the
rats to manipulation. Animals were randomly assigned
to experimental groups and were used only once in the
behavioralexperiments.Thebehavioraltestswereconducted
between 10:00 AM and 2:00 PM. Experiments were carried
out in a soundproof and air-regulated experimental room,
to which animals were habituated at least 30min before each
test.
2.2. Surgery. Ovariectomy was performed through an
abdominal ventral incision under ethylic ether anesthesia.
The complete extraction of the ovaries was corroborated by
visual inspection. After the surgery the rats were retrieved
in a community cage with other rats. Eﬃciency of 17β-E2
administration to OVX females was controlled by vaginal
smears. OVX animals were allowed to have 14 days for
postoperative recovery before administration of drugs. After
two weeks, all OVX rats were randomly assigned to each of
the experimental groups and subjected to treatments andISRN Pharmacology 3
behavioral tests. We used 14 days for postoperative recovery
before administration of drugs because of estrogen depletion
induced by ovariectomy results in a marked decrease in
dopaminergic cell density in the brain [43], an eﬀect that can
be reversed by estrogen administration 14 days after ovariec-
tomy. Thus, 17β-E2 or dopaminergic drugs administration
in 14 days after ovariectomy would still be able to change
the activity of dopaminergic neurons, whereas it looses this
capability after longer period of estrogen depletion when at
least part of the mesocortical dopamine neurons might be
inactive or dead.
2.3. Drugs. D2 receptor agonist (−)-quinpirole hydrochlo-
ride (Q-102, Sigma Chemical Co) was dissolved in sterile
saline (0.9%). D2 receptor antagonist (S)-(−)-sulpiride (S-
7771, Sigma Chemical Co) was dissolved in a constant
volume of 0.1 NHCl, then neutralized with 0.1M NaHCO3
(pH 6.9) and brought up to volume. The estrogen, 17β-
E2 (E-8875, Sigma Chemical Co.) was dissolved in sterile
sesame oil. All solutions were freshly prepared before each
experimental series. Drugs were administered during 14 days
after postoperative period following ovariectomy. Dopamin-
ergic chemicals were injected s.c. or i.p. in volume of 0.1mL.
Control OVX rats received oil solvent injection in the same
volume.
2.4. Experimental Groups. For performance of behavioral
tests OVX rats were divided into six groups of 10 animals in
each. The rats used for forced swimming test and locomotor
test were the same. The ﬁrst group was constituted of OVX
rats treated with oil solvent subcutaneously (control). The
ﬁve other groups were of OVX rats treated with 17β-E2
(5.0μkg/rat, s.c.) daily; OVX rats injected with quinpirole
(0.1mg/kg, i.p.) daily; OVX females injected with sulpiride
(10.0mg/kg, i.p.) daily; OVX rats treated with quinpirole
in combination with 17β-E2 in the same dose which was
given to OVX rats; OVX females with sulpiride daily in
combinationwith17β-E2 inthesamedosewhichwasapplied
to OVX females. All preparations were chronically injected
f o r1 4d a y so n c ed a i l yt h r o u g ha l lb e h a v i o r a ls e s s i o n s( i . e . ,
in the forced swimming test treatment was made on the ﬁrst
dayandtheseconddaytoo).Allbehavioralexperimentswere
done in 45min after the last injection of the drugs.
2.5.DeterminingOptimalDosingforSulpirideandQuinpirole.
The motor behavior can be attributed to altered immobility,
swimming and struggling observed in the forced swimming
test. Because of it, we used locomotor activity test for deter-
mination of optimal dosing for dopaminergic drugs, since
behavioral studies indicated that DA drugs may inﬂuence
on motor activity of rats [44–46], and we did not have
any way to predict the doses of DA drugs that failed to
induce deeply marked changes of the locomotor activity. In
a preliminary experiment the dose-eﬀect relationship of DA
drugs after acute administration compared with saline in
the OVX rats was studied in the locomotor activity test. We
injected diﬀerent doses of sulpiride (1.0–10.0mg/kg, i.p.),
quinpirole (0.05–0.2mg/kg, i.p.), or saline 45min before
testing. We found that the 10.0mg/kg dose of sulpiride and
the 0.1mg/kg dose did not change locomotor activity. These
doses of DA drugs were selected for the succeeding forced
swimming test. Furthermore, these doses were considered as
theminimumbehavioraldosesfortheOVXratsthatfailedto
induce any alteration in the motor behavior. The low dose of
17β-E2 (5.0μg/rat) was chosen from the studies performed
by [47, 48].
2.6. Behavioral Tests
2.6.1. Forced Swimming Test. Rats were individually forced
to swim inside vertical Plexiglas cylinders containing water
maintained at 25◦C (modiﬁed from Porsolt et al. [42]).
The behavioral cylinder was 60cm high and 20cm wide
maintained at 25◦C, ﬁlled with 30cm of water, so that rats
could not support themselves by touching the bottom with
their paws or tail. The FST included 2 phases: an initial
15min pretest followed by a 5min test 24h later. After each
session, the rats were removed from the cylinders, dried with
towels, and placed into heated cages for 10min, and then
returned to their home cages. Total duration of immobility,
total duration of struggling, and total duration of swimming
were measured during a 5min test. A rat was judged to
be immobile whenever it remained passively ﬂoating in the
water in a slightly hunched but upright position, its head just
above the surface. Struggling was considered when the rats
make active movements with their forepaws in and out of
thewateralongthesideoftheswimchamber.Swimmingwas
considered when the rats make active swimming or circular
movements. A video camera was installed above the model
to recode the rat activity in the test.
2.6.2. Locomotor Activity Test. To evaluate the eﬀect of treat-
ments on spontaneous motor activity all experimen-
tal groups were submitted to the locomotor activity test.
Horizontal activity was measured for 5min using Plexiglas
cage (20cm × 40 × 23cm) placed into a photobeam appara-
tus (Opto-Varimex, Columbus, OH): 15 photobeams cross
the width of the cage 2.5cm apart and 8cm above the
cage ﬂoor. The locomotor activity was recorded by a video-
camera and subsequently evaluated by two distinct observers
unaware of treatment assignment of experimental groups.
After each test session, the apparatus was carefully cleaned
and deodorized with a cleaning solution (ammonia 0.5%,
ethanol 15%, extran 10%, isopropyl alcohol 5%, antiseptic
with aromatizing 19%, and distillated water 50.5%).
2.7. Statistical Analysis. A l lv a l u e sw e r ee x p r e s s e da sm e a n±
S.E.M. Comparisons between values were performed using
two-way ANOVA test with between-subject factors of hor-
mone condition (OVX or OVX plus 17β-E2) and drug treat-
ment (vehicle, quinpirole, or sulpiride) followed by Dun-
nett’s test for multiple comparisons post hoc test. Statistical
analysis was performed using SPSS version 11.5. Diﬀerences
with P<0.05 were considered signiﬁcant.4 ISRN Pharmacology
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Figure 1: Eﬀects of dopaminergic drugs alone or in combination with 17β-E2 on depressive-like behavior of the OVX rats. Columns
represent the immobility time (a), struggling duration (b), and swimming duration (c) in the forced swimming test mean ± SEM (in
sec). Each group comprised of ten rats. ∗P<0.05 versus control group of rats, #P<0.05 versus OVX rats treated with 17β-E2.
3. Results
3.1. Forced Swimming Test. The two-way ANOVA revealed
signiﬁcant diﬀerences in immobility time between hormone
conditions (F4,30 = 7.39, P<0.0004), between drug treat-
ments (F3,90 = 12.05, P<0.0003), and an interaction
between hormone condition and treatments (F1,56 = 2.87,
P<0.01). The post-hoc test revealed diﬀerences among the
groups for depression-like behavior in the FST (P<0.0001).
Repeated 17β-E2 administration in low dose to the OVX
rats signiﬁcantly reduced immobility time compared to the
control(Figure 1(a)).Afterrepeatedtreatment,neitherquin-
pirole (0.1mg/kg) alone nor quinpirole combined with 17β-
E2 had any signiﬁcant eﬀect on immobility behavior in the
OVX rats (post hoc versus control group, both P>0.05).
Interestingly, the administration of quinpirole together with
17β-E2 in OVX rats completely abolished the reduction of
immobility behavior induced by 17β-E2 (post hoc versus
OVX group treated with 17β-E2, P<0.05; Figure 1(a)). The
D2 receptor antagonist, sulpiride (0.1mg/kg) signiﬁcantly
decreased immobility time compared to OVX rats (P<0.05;
Figure 1(a)). Combined administration of sulpiride with
17β-E2 in the OVX rats resulted in a profound reduction
of immobility behavior (post hoc versus control group and
OVX group treated with 17β-E2, P<0.05). It should be
noted that the repeated administration of this combination
potentiated the positive eﬀects of sulpiride and 17β-E2 on
immobility behavior in the OVX rats.
The two-way ANOVA revealed signiﬁcant diﬀerences
in swimming time between hormone conditions (F3,90 =
15.77, P<0.01), between drug treatments (F2,80 = 9.44,
P<0.05), and an interaction between hormone condition
and treatments (F2,54 = 7.43, P<0.001). Repeated 17β-
E2 administration in low dose to the OVX rats signiﬁ-
cantly increased swimming time compared to the control
(Figure 1(b)). After repeated treatment, neither quinpirole
(0.1mg/kg) alone nor quinpirole combined with 17β-E2 had
any signiﬁcant eﬀect on swimming time in the OVX rats
(Posthoc,versuscontrolgroup,bothP>0.05).Interestingly,
the administration of quinpirole together with 17β-E2 in
OVX rats completely inhibited the increase of swimming
time induced by 17β-E2 (post hoc versus OVX group treated
with17β-E2, P<0.05; Figure 1(b)). The D2 receptor antago-
nist, sulpiride (0.1mg/kg) signiﬁcantly increased swimming
time compared to OVX rats (P<0.05; Figure 1(b)). Com-
bined administration of sulpiride with 17β-E2 in the OVXISRN Pharmacology 5
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Figure 2: Eﬀects of dopaminergic drugs alone or in combination
with 17β-E2 on the locomotor activity of the OVX rats. Data are
presentedastotalhorizontalactivitycounts(photobeambreaks)for
the 5min test (mean ± SEM). Each group comprised of ten rats.
rats resulted in a profound enhancement of swimming time
(post hoc versus control group and OVX group treated with
17β-E2, P<0.05). It should be noted that the repeated
administration of this combination potentiated the positive
eﬀects of sulpiride and 17β-E2 on swimming behavior in the
OVX rats. No signiﬁcant diﬀerences due to the repeated drug
treatments or hormonal condition were observed for strug-
gling time (post hoc versus control group, both P>0.05,
Figure 1(c)).
3.2. Locomotor Activity Test. To determine whether quin-
pirole- or sulpiride-induced changes in behavior of the
OVX rats in the FST could be due to nonspeciﬁc eﬀects
of dopaminergic ligands and 17β-E2 on locomotor activity,
spontaneous locomotor activity was assessed in a separate
groups of the OVX rats treated with 17β-E2 (5.0μkg/rat,
s.c.) daily, OVX rats injected with quinpirole (0.1mg/kg,
i.p.) daily, OVX females injected with sulpiride (0.1mg/kg,
i.p.) daily, OVX rats treated with quinpirole in combination
with 17β-E2 in the same dose which was given to OVX rats,
and OVX females with quinpirole daily in combination with
17β-E2. The two-way ANOVA failed to reveal any signiﬁcant
diﬀerences in the locomotor activity between hormone
conditions (F3,14 = 29.41, P>0.05; Figure 2), between
drug treatments (F3,14 = 12.78, P>0.01; Figure 2), and
an interaction between hormone condition and treatments
(F1,54 = 11.56, P>0.05; Figure 2). The post hoc test failed to
reveal diﬀerences among the groups for this parameter in the
test (P>0.05).
4. Discussion
Results of the present study support previous evidence that
depression-like behavior is inﬂuenced by estrogen depletion
and by low dose of 17β-E2 administration to OVX rats
[23, 33]. We found that ovariectomy produced an increase of
immobility time and substitution treatment with low dose of
17β-E2 in OVX rats partially attenuated this parameter. The
data received in the present study are in a good agreement
with our previous data [31, 32]. We found previously that
ovariectomy and phases of ovary cycle aﬀect the behavioral
response in a model of behavioral despair, exhibiting a
longer immobility time as compared to diestrous animals
[31, 32]. Also, our previous data have suggested that 17β-
E2 administration produced an antidepressant-like eﬀect in
ovariectomized rats [32, 49].
However, the major ﬁnding of the present study is
that drugs inﬂuencing DA transmission can also modify
depression-like behavior in female animals with diﬀerent
hormonelevelsoccurringafterovariectomyandafter17β-E2
administration. In our experiments chronic administration
of selective D2 receptor antagonist sulpiride in OVX females
decreased immobility time in the FST, that is, sulpiride
exerted deﬁnite antidepressant-like action. Also, chronic
treatment with sulpiride and low dose of 17β-E2 induced a
more relevant antidepressant-like eﬀect in OVX rats. These
eﬀects were similar to those of the classical antidepressant
clomipramine in OVX rats as we demonstrated in our
previous study [32]. The data from the present study suggest
that sulpiride and 17β-E2 exert synergic positive eﬀects
on depression-like behavior and can potentiate eﬀects of
each other. Some reports have also showed that repeated
administrationof17β-E2 inlowdosewithserotonergicdrugs
may have the same synergic positive eﬀects on depression-
like behavior [47, 48] as we found using combination
of dopaminergic drugs with 17β-E2 in low dose. On the
other hand, chronic administration of selective D2 receptor
agonist quinpirole failed to modify the depression-like
behavior of OVX rats in the FST. Interestingly, quinpirole
signiﬁcantly blocked the antidepressant-like eﬀect of 17β-
E2. Pharmacological studies have demonstrated that the
central DA neuronal system may functionally be involved
in depression-like behavior [5–7]. Some data suggest that
selective D2 agonists have antidepressant eﬀects in both
learned helplessness procedure and the forced swimming
test in male rats, while blockade of D2 receptors prevents
the antidepressant eﬀect of imipramine as well as other
agents [15, 24, 25, 50]. However, our present results are
in good agreement with data of others [51–53], showing
that some dopaminergic antipsychotic drugs acting as DA
receptor antagonists are also active as antidepressants. In
our experimental conditions there was no direct relation
between the eﬀects of D2 receptor agonist or antagonist on
depression-like behavior and behavioral changes observed
in the locomotor activity test. Since neither 17β-E2 nor
sulpiride signiﬁcantly inﬂuenced behavior in the locomo-
tor activity test, the antidepressant synergy observed in
the FST—decreased immobility and increased swimming—
cannot be attributed to increased locomotor activation.
Instead, results from the FST and locomotor behavioral tests
considered together indicate that the interaction between
17β-E2 and sulpiride is a hedonic rather that a motor
eﬀect. Also, the data of literature suggest that D2 receptor
antagonist sulpiride was able to increase the immobility
time in the FST in mice at dose (20.0mg/kg, i.p.) which
increased motor activity [54]. Here, in our experimental
conditions we used sulpiride in a dose of 10.0mg/kg for
OVX females which failed to change locomotor activity.6 ISRN Pharmacology
Thus, our results demonstrated that action of D2 receptor
antagonist on depression-like is dependent from the used
dose and gender of animals and D2 receptor antagonist
may possess antidepressant activity as it was shown in some
reports [55, 56].
Sulpiride is the oldest and clinically most established
member of the substituted benzamides. It binds to D2/D3
receptors that may be located on the presynaptic membrane
[57].Furthermore,sulpiridehasbeenfoundtoincreasebrain
dopamine synthesis [58]. The mechanism of the antidepres-
sant action of sulpiride seems to involve the block of the
dopaminergic system and a possible D1 and D2 receptors
sensitization in the mesolimbic area [21]. The eﬀectiveness
of sulpiride in experimental models of depression conﬁrm
its beneﬁcial eﬀect in various types of depression in men [59,
60]. Since an antidepressant action has been described for
dopamine agonists such as bromocriptine and piribedil [55,
60], it may be surprising that under certain circumstances
neuroleptics acting as dopamine receptor antagonists are
also active as antidepressants. This has been proved not
only for sulpiride but also for other neuroleptics [61] that
may act preferentially as presynaptic dopamine receptor
antagonists, thus increasing dopamine turnover. In our
preliminary experiments, we were not able to ﬁnd any
eﬀects for D2 receptor agonist quinpirole and D2 receptor
antagonist sulpiride after acute administration alone or in
combination with 17β-E2 on depression-like behavior in
adult OVX rats (data are not shown). However, based on the
results of the present study, it can be assumed that eﬀects of
DAdrugsarediﬀerentafteracuteandchronicadministration
in OVX rats. Thus, the behavioral eﬀects of DA drugs alone
or in combination with 17β-E2 after repeated treatment may
due to any adaptive changes in the brain.
It should be noted that one limitation in interpretation
of the present ﬁndings is that sulpiride, in common with
virtually all “selective” D2 receptor antagonists and agonists,
exhibits aﬃnity for the D3 as well as the D2 receptor [62].
Although D3 receptors appear to be preferentially located to
the ventral rather than the dorsal striatum, there is evidence
of some expression of D3 receptors in the putamen [63]
and so it cannot be excluded that some of the eﬀects of
sulpiride described here are due its antagonism of that
receptor. An alternative explanation for the improvement in
despair behavior after sulpiride is that it is actually due to
a drug-induced increase in extracellular DA. Animal studies
have shown that relatively low single doses of DA antagonists
such as sulpiride and haloperidol increase levels of striatal
DA [62, 63] by inhibiting the presynaptic activity of DA
autoreceptors [62]. This increased DA will hit D1 receptors
and thus behavioural improvements after sulpiride may in
fact be attributable to the increase in extracellular striatal
DA induced by downregulation of presynaptic activity.
Also, it should be noted that ovariectomy of female rats
results in a decrease in dopamine-speciﬁc proteins, including
dopamine receptors and dopamine transporters. 17β-E2
administration can restore these functional responses [63–
65]. In this connection, it can be assumed that profound
positive eﬀect of sulpiride in a combination with 17β-
E2 on despair behavior in OVX rats may due to their
mutual positive actions on dopaminergic system. Thus,
the depression-like state, which was prevented by sulpiride
in OVX rats could be considered as part of an estrogen
withdrawal syndrome, or the expression of genomic actions
of this hormone. The precise mechanism by which sulpiride
aloneorinacombinationwith17β-E2 inducedpositiveeﬀect
on depression-like behavior in the present study remains to
be established.
There is no doubt that female gonadal hormones may
act directly or indirectly to have inﬂuence on the diﬀerent
neurotransmitter systems, especially serotonergic system,
which in turn, modulate DA activity [28, 29]. Considering
that sulpiride is a selective D2 receptor antagonist, one may
suppose that its antidepressant eﬀect in OVX rats with
or without 17β-E2 treatment could be correlated with a
previous hyperactivity of diﬀerent neurotransmitter systems.
Themaininterestingresultfromthisstudyisthatquinpirole,
selective D2 receptor agonist, inhibited antidepressant-like
eﬀect of 17β-E2 in the FST. Some evidence has shown that
ERs can be activated by dopaminergic ligands acting on D2
receptors [40]. One may assume that quinpirole could be
present to binding of 17β-E2 with ERs resulting in blockade
of positive action of 17β-E2 on depression-like behavior in
OVXrats.However,itseemstobeverydiﬃculttodrawclear-
cut conclusion on the exact nature interactions between DA
and estrogens in the mechanisms of mood disorders.
It should be emphasized that in studies dealing with
dopamine-aﬀective interactions only male animals were
usually used as subjects. Also, no comparative analysis of
eﬀects of selective agonists or antagonists of D2 receptors on
d e s p a i rb e h a v i o ri nO V Xf e m a l e sh a sb e e np e r f o r m e ds of a r .
Diverging eﬀects of quinpirole and sulpiride in OVX females
in our experiments can be related to changed metabolism
of DA, expression of D2 receptors, expression of 17β-E2
receptors, and to their binding ability in the brain structures
directly related to mood functions. In summary, the D2
receptor antagonist, sulpiride administered alone, or in a
combination with a low dose of 17β-E2 resulted in an
antidepressant-like eﬀect in the OVX rats. Repeated treat-
ment with sulpiride and a low dose of 17β-E2 profoundly
enhanced antidepressant-like eﬀects the single substances
exert per se. The D2 receptor agonist, quinpirole failed to
modify the depression-like behavior of OVX rats in the
FST. In addition, quinpirole blocked the antidepressant-like
eﬀect of 17β-E2 in OVX rats. Further research is needed to
elucidate the detailed mechanisms by which sulpiride and
17β-E2 exert synergic eﬀect and aﬀect the dopaminergic
system. This study provides additional evidence to support
the role of dopaminergic mechanisms in depression-like
behavior and contributes to the better understanding of the
complex interaction between estrogens and DA neurotrans-
mitter systems.
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